Orbit alveolar rhabdomyosarcoma

Summary

Orbit alveolar rhabdomyosarcoma (MONDO:0002978) is a disease. A subtype of orbit rhabdomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	orbit alveolar rhabdomyosarcoma
Mondo ID	MONDO:0002978
DOID	DOID:4384
NCIT	C6247
UMLS	C1335126
MedGen	235408
GARD	0023311
Is cancer (heuristic)	no

Also known as: alveolar rhabdomyosarcoma of orbit · alveolar rhabdomyosarcoma of the orbit

Disease family

This is a subtype of orbit rhabdomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › skull cancer › orbital cancer › orbit sarcoma › orbit rhabdomyosarcoma › orbit alveolar rhabdomyosarcoma

Related subtypes (1): orbit embryonal rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.